Supplement analysis backed by scientific evidence · PT

← All supplements
Moderate evidenceJoints & skin

Chondroitin Sulfate

Heavily studied and genuinely mixed: pooled analyses show a small pain benefit in knee osteoarthritis, but the effect shrinks as trial quality rises, and the largest independent trial was null. It is very safe, so the real question is whether a modest, uncertain benefit is worth the cost.

What the science says

  • Osteoarthritis pain Moderate evidence

    A Cochrane review of 43 randomized trials in 4,962 participants found chondroitin reduced pain by about 10 points more than placebo on a 100-point scale in trials under 6 months — but rated the evidence quality low, and the benefit shrank substantially when analysis was restricted to larger, adequately blinded, non-industry trials. Effect size in the best trials falls below the threshold generally considered clinically meaningful.

  • The largest independent trial was negative Moderate evidence

    The NIH-funded GAIT trial randomized 1,583 people with knee osteoarthritis; chondroitin sulfate 1,200 mg/day did not significantly outperform placebo on the primary outcome (a 20% reduction in WOMAC pain), with response rates of roughly 65% versus 60%. A benefit for glucosamine plus chondroitin appeared only in an exploratory moderate-to-severe pain subgroup and was not confirmed by later work.

  • Slowing joint space narrowing Limited evidence

    Cochrane pooling found a small statistically significant benefit on minimum joint space width (standardised mean difference around -0.18) in longer trials, but the absolute difference is fractions of a millimetre and its relationship to symptoms or joint replacement rates is unestablished. Calling chondroitin "structure-modifying" overstates what the imaging data support.

  • Product quality and label accuracy Limited evidence

    Independent testing has repeatedly found US chondroitin supplements containing substantially less than labeled, sometimes under half. Since chondroitin is expensive to manufacture, this is a persistent problem and a plausible contributor to inconsistent trial results — European trials often used pharmaceutical-grade material that US consumers cannot buy.

Dosage & safety

Studied doseTrials used chondroitin sulfate 800-1,200 mg/day, taken as a single dose or split, for 3-24 months. It is frequently combined with glucosamine sulfate or hydrochloride at 1,500 mg/day. Give it at least 8-12 weeks; several trials found effects emerged slowly.
SafetySafety is the strongest part of chondroitin's profile — Cochrane found adverse event rates no different from placebo, with mild GI symptoms the main complaint. Most product is derived from bovine trachea, porcine or shark cartilage, which matters for religious, dietary or allergy reasons (shellfish allergy is more relevant to glucosamine than chondroitin). Case reports and some analyses suggest chondroitin, particularly combined with glucosamine, may potentiate warfarin and raise INR — monitor closely if anticoagulated. In several European countries chondroitin is a prescription or licensed medicine classed as a symptomatic slow-acting drug for osteoarthritis, whereas in the US it is an unregulated supplement; buy third-party tested product. Avoid in pregnancy and lactation for lack of data.

Scientific references

Where to buy

NOW Foods, Chondroitin Sulfate, 600 mg, 120 Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Joints & skin